



















Case	Model	Method	Time (s)	Memory (MB)	Iterations	Convergence
1	M1	Newton	1.2	10	10	Yes
		Quasi-Newton	1.5	10	10	Yes
2	M2	Newton	1.5	10	10	Yes
		Quasi-Newton	1.8	10	10	Yes
3	M3	Newton	1.8	10	10	Yes
		Quasi-Newton	2.0	10	10	Yes
4	M4	Newton	2.0	10	10	Yes
		Quasi-Newton	2.2	10	10	Yes
5	M5	Newton	2.2	10	10	Yes
		Quasi-Newton	2.5	10	10	Yes
6	M6	Newton	2.5	10	10	Yes
		Quasi-Newton	2.8	10	10	Yes
7	M7	Newton	2.8	10	10	Yes
		Quasi-Newton	3.0	10	10	Yes
8	M8	Newton	3.0	10	10	Yes
		Quasi-Newton	3.2	10	10	Yes
9	M9	Newton	3.2	10	10	Yes
		Quasi-Newton	3.5	10	10	Yes
10	M10	Newton	3.5	10	10	Yes
		Quasi-Newton	3.8	10	10	Yes

1.  $\frac{1}{2}$   
 2.  $\frac{1}{3}$   
 3.  $\frac{1}{4}$   
 4.  $\frac{1}{5}$   
 5.  $\frac{1}{6}$   
 6.  $\frac{1}{7}$   
 7.  $\frac{1}{8}$   
 8.  $\frac{1}{9}$   
 9.  $\frac{1}{10}$   
 10.  $\frac{1}{11}$   
 11.  $\frac{1}{12}$   
 12.  $\frac{1}{13}$   
 13.  $\frac{1}{14}$   
 14.  $\frac{1}{15}$   
 15.  $\frac{1}{16}$   
 16.  $\frac{1}{17}$   
 17.  $\frac{1}{18}$   
 18.  $\frac{1}{19}$   
 19.  $\frac{1}{20}$   
 20.  $\frac{1}{21}$   
 21.  $\frac{1}{22}$   
 22.  $\frac{1}{23}$   
 23.  $\frac{1}{24}$   
 24.  $\frac{1}{25}$   
 25.  $\frac{1}{26}$   
 26.  $\frac{1}{27}$   
 27.  $\frac{1}{28}$   
 28.  $\frac{1}{29}$   
 29.  $\frac{1}{30}$   
 30.  $\frac{1}{31}$   
 31.  $\frac{1}{32}$   
 32.  $\frac{1}{33}$   
 33.  $\frac{1}{34}$   
 34.  $\frac{1}{35}$   
 35.  $\frac{1}{36}$   
 36.  $\frac{1}{37}$   
 37.  $\frac{1}{38}$   
 38.  $\frac{1}{39}$   
 39.  $\frac{1}{40}$   
 40.  $\frac{1}{41}$   
 41.  $\frac{1}{42}$   
 42.  $\frac{1}{43}$   
 43.  $\frac{1}{44}$   
 44.  $\frac{1}{45}$   
 45.  $\frac{1}{46}$   
 46.  $\frac{1}{47}$   
 47.  $\frac{1}{48}$   
 48.  $\frac{1}{49}$   
 49.  $\frac{1}{50}$   
 50.  $\frac{1}{51}$   
 51.  $\frac{1}{52}$   
 52.  $\frac{1}{53}$   
 53.  $\frac{1}{54}$   
 54.  $\frac{1}{55}$   
 55.  $\frac{1}{56}$   
 56.  $\frac{1}{57}$   
 57.  $\frac{1}{58}$   
 58.  $\frac{1}{59}$   
 59.  $\frac{1}{60}$   
 60.  $\frac{1}{61}$   
 61.  $\frac{1}{62}$   
 62.  $\frac{1}{63}$   
 63.  $\frac{1}{64}$   
 64.  $\frac{1}{65}$   
 65.  $\frac{1}{66}$   
 66.  $\frac{1}{67}$   
 67.  $\frac{1}{68}$   
 68.  $\frac{1}{69}$   
 69.  $\frac{1}{70}$   
 70.  $\frac{1}{71}$   
 71.  $\frac{1}{72}$   
 72.  $\frac{1}{73}$   
 73.  $\frac{1}{74}$   
 74.  $\frac{1}{75}$   
 75.  $\frac{1}{76}$   
 76.  $\frac{1}{77}$   
 77.  $\frac{1}{78}$   
 78.  $\frac{1}{79}$   
 79.  $\frac{1}{80}$   
 80.  $\frac{1}{81}$   
 81.  $\frac{1}{82}$   
 82.  $\frac{1}{83}$   
 83.  $\frac{1}{84}$   
 84.  $\frac{1}{85}$   
 85.  $\frac{1}{86}$   
 86.  $\frac{1}{87}$   
 87.  $\frac{1}{88}$   
 88.  $\frac{1}{89}$   
 89.  $\frac{1}{90}$   
 90.  $\frac{1}{91}$   
 91.  $\frac{1}{92}$   
 92.  $\frac{1}{93}$   
 93.  $\frac{1}{94}$   
 94.  $\frac{1}{95}$   
 95.  $\frac{1}{96}$   
 96.  $\frac{1}{97}$   
 97.  $\frac{1}{98}$   
 98.  $\frac{1}{99}$   
 99.  $\frac{1}{100}$   
 100.  $\frac{1}{101}$   
 101.  $\frac{1}{102}$   
 102.  $\frac{1}{103}$   
 103.  $\frac{1}{104}$   
 104.  $\frac{1}{105}$   
 105.  $\frac{1}{106}$   
 106.  $\frac{1}{107}$   
 107.  $\frac{1}{108}$   
 108.  $\frac{1}{109}$   
 109.  $\frac{1}{110}$   
 110.  $\frac{1}{111}$   
 111.  $\frac{1}{112}$   
 112.  $\frac{1}{113}$   
 113.  $\frac{1}{114}$   
 114.  $\frac{1}{115}$   
 115.  $\frac{1}{116}$   
 116.  $\frac{1}{117}$   
 117.  $\frac{1}{118}$   
 118.  $\frac{1}{119}$   
 119.  $\frac{1}{120}$   
 120.  $\frac{1}{121}$   
 121.  $\frac{1}{122}$   
 122.  $\frac{1}{123}$   
 123.  $\frac{1}{124}$   
 124.  $\frac{1}{125}$   
 125.  $\frac{1}{126}$   
 126.  $\frac{1}{127}$   
 127.  $\frac{1}{128}$   
 128.  $\frac{1}{129}$   
 129.  $\frac{1}{130}$   
 130.  $\frac{1}{131}$   
 131.  $\frac{1}{132}$   
 132.  $\frac{1}{133}$   
 133.  $\frac{1}{134}$   
 134.  $\frac{1}{135}$   
 135.  $\frac{1}{136}$   
 136.  $\frac{1}{137}$   
 137.  $\frac{1}{138}$   
 138.  $\frac{1}{139}$   
 139.  $\frac{1}{140}$   
 140.  $\frac{1}{141}$   
 141.  $\frac{1}{142}$   
 142.  $\frac{1}{143}$   
 143.  $\frac{1}{144}$   
 144.  $\frac{1}{145}$   
 145.  $\frac{1}{146}$   
 146.  $\frac{1}{147}$   
 147.  $\frac{1}{148}$   
 148.  $\frac{1}{149}$   
 149.  $\frac{1}{150}$   
 150.  $\frac{1}{151}$   
 151.  $\frac{1}{152}$   
 152.  $\frac{1}{153}$   
 153.  $\frac{1}{154}$   
 154.  $\frac{1}{155}$   
 155.  $\frac{1}{156}$   
 156.  $\frac{1}{157}$   
 157.  $\frac{1}{158}$   
 158.  $\frac{1}{159}$   
 159.  $\frac{1}{160}$   
 160.  $\frac{1}{161}$   
 161.  $\frac{1}{162}$   
 162.  $\frac{1}{163}$   
 163.  $\frac{1}{164}$   
 164.  $\frac{1}{165}$   
 165.  $\frac{1}{166}$   
 166.  $\frac{1}{167}$   
 167.  $\frac{1}{168}$   
 168.  $\frac{1}{169}$   
 169.  $\frac{1}{170}$   
 170.  $\frac{1}{171}$   
 171.  $\frac{1}{172}$   
 172.  $\frac{1}{173}$   
 173.  $\frac{1}{174}$   
 174.  $\frac{1}{175}$   
 175.  $\frac{1}{176}$   
 176.  $\frac{1}{177}$   
 177.  $\frac{1}{178}$   
 178.  $\frac{1}{179}$   
 179.  $\frac{1}{180}$   
 180.  $\frac{1}{181}$   
 181.  $\frac{1}{182}$   
 182.  $\frac{1}{183}$   
 183.  $\frac{1}{184}$   
 184.  $\frac{1}{185}$   
 185.  $\frac{1}{186}$   
 186.  $\frac{1}{187}$   
 187.  $\frac{1}{188}$   
 188.  $\frac{1}{189}$   
 189.  $\frac{1}{190}$   
 190.  $\frac{1}{191}$   
 191.  $\frac{1}{192}$   
 192.  $\frac{1}{193}$   
 193.  $\frac{1}{194}$   
 194.  $\frac{1}{195}$   
 195.  $\frac{1}{196}$   
 196.  $\frac{1}{197}</$

[illegible][illegible]

the authors are grateful to the referees for their valuable comments and suggestions.

1. *Journal of the American Medical Association*, 1997; 277: 103-107.

1. *Supernova 1994, 1*, Aff  
 2. *Supernova 1994, 2*, Aff  
 3. *Supernova 1994, 3*, Aff  
 4. *Supernova 1994, 4*, Aff  
 5. *Supernova 1994, 5*, Aff  
 6. *Supernova 1994, 6*, Aff  
 7. *Supernova 1994, 7*, Aff  
 8. *Supernova 1994, 8*, Aff  
 9. *Supernova 1994, 9*, Aff  
 10. *Supernova 1994, 10*, Aff  
 11. *Supernova 1994, 11*, Aff  
 12. *Supernova 1994, 12*, Aff  
 13. *Supernova 1994, 13*, Aff  
 14. *Supernova 1994, 14*, Aff  
 15. *Supernova 1994, 15*, Aff  
 16. *Supernova 1994, 16*, Aff  
 17. *Supernova 1994, 17*, Aff  
 18. *Supernova 1994, 18*, Aff  
 19. *Supernova 1994, 19*, Aff  
 20. *Supernova 1994, 20*, Aff  
 21. *Supernova 1994, 21*, Aff  
 22. *Supernova 1994, 22*, Aff  
 23. *Supernova 1994, 23*, Aff  
 24. *Supernova 1994, 24*, Aff  
 25. *Supernova 1994, 25*, Aff  
 26. *Supernova 1994, 26*, Aff  
 27. *Supernova 1994, 27*, Aff  
 28. *Supernova 1994, 28*, Aff  
 29. *Supernova 1994, 29*, Aff  
 30. *Supernova 1994, 30*, Aff  
 31. *Supernova 1994, 31*, Aff  
 32. *Supernova 1994, 32*, Aff  
 33. *Supernova 1994, 33*, Aff  
 34. *Supernova 1994, 34*, Aff  
 35. *Supernova 1994, 35*, Aff  
 36. *Supernova 1994, 36*, Aff  
 37. *Supernova 1994, 37*, Aff  
 38. *Supernova 1994, 38*, Aff  
 39. *Supernova 1994, 39*, Aff  
 40. *Supernova 1994, 40*, Aff  
 41. *Supernova 1994, 41*, Aff  
 42. *Supernova 1994, 42*, Aff  
 43. *Supernova 1994, 43*, Aff  
 44. *Supernova 1994, 44*, Aff  
 45. *Supernova 1994, 45*, Aff  
 46. *Supernova 1994, 46*, Aff  
 47. *Supernova 1994, 47*, Aff  
 48. *Supernova 1994, 48*, Aff  
 49. *Supernova 1994, 49*, Aff  
 50. *Supernova 1994, 50*, Aff  
 51. *Supernova 1994, 51*, Aff  
 52. *Supernova 1994, 52*, Aff  
 53. *Supernova 1994, 53*, Aff  
 54. *Supernova 1994, 54*, Aff  
 55. *Supernova 1994, 55*, Aff  
 56. *Supernova 1994, 56*, Aff  
 57. *Supernova 1994, 57*, Aff  
 58. *Supernova 1994, 58*, Aff  
 59. *Supernova 1994, 59*, Aff  
 60. *Supernova 1994, 60*, Aff  
 61. *Supernova 1994, 61*, Aff  
 62. *Supernova 1994, 62*, Aff  
 63. *Supernova 1994, 63*, Aff  
 64. *Supernova 1994, 64*, Aff  
 65. *Supernova 1994, 65*, Aff  
 66. *Supernova 1994, 66*, Aff  
 67. *Supernova 1994, 67*, Aff  
 68. *Supernova 1994, 68*, Aff  
 69. *Supernova 1994, 69*, Aff  
 70. *Supernova 1994, 70*, Aff  
 71. *Supernova 1994, 71*, Aff  
 72. *Supernova 1994, 72*, Aff  
 73. *Supernova 1994, 73*, Aff  
 74. *Supernova 1994, 74*, Aff  
 75. *Supernova 1994, 75*, Aff  
 76. *Supernova 1994, 76*, Aff  
 77. *Supernova 1994, 77*, Aff  
 78. *Supernova 1994, 78*, Aff  
 79. *Supernova 1994, 79*, Aff  
 80. *Supernova 1994, 80*, Aff  
 81. *Supernova 1994, 81*, Aff  
 82. *Supernova 1994, 82*, Aff  
 83. *Supernova 1994, 83*, Aff  
 84. *Supernova 1994, 84*, Aff  
 85. *Supernova 1994, 85*, Aff  
 86. *Supernova 1994, 86*, Aff  
 87. *Supernova 1994, 87*, Aff  
 88. *Supernova 1994, 88*, Aff  
 89. *Supernova 1994, 89*, Aff  
 90. *Supernova 1994, 90*, Aff  
 91. *Supernova 1994, 91*, Aff  
 92. *Supernova 1994, 92*, Aff  
 93. *Supernova 1994, 93*, Aff  
 94. *Supernova 1994, 94*, Aff  
 95. *Supernova 1994, 95*, Aff  
 96. *Supernova 1994, 96*, Aff  
 97. *Supernova 1994, 97*, Aff  
 98. *Supernova 1994, 98*, Aff  
 99. *Supernova 1994, 99*, Aff  
 100. *Supernova 1994, 100*, Aff

1 RESULTS: 1  
 2 1. Sponsoring Agency: Federal Bureau of Investigation  
 3 Patent No. 44-38842  
 4 GENERAL INFORMATION  
 5 APPLICANT: International Telephone and Telegraph Company  
 6 APPLICANT'S Address: 400 Madison Avenue  
 7 APPLICANT'S City: New York, New York  
 8 TITLE OF INVENTION: Method of Securing Telephone Calls  
 9 TITLE OF INVENTOR: William J. O'Brien  
 10 NUMBER OF SEQUENCES: 1  
 11 CORRESPONDENCE ADDRESS:  
 12 ADDRESS: 400 Madison Avenue  
 13 CITY: New York, New York  
 14 STATE: NY  
 15 COUNTRY: USA  
 16 OTHER READING ROOM:  
 17 METHOD TYPE: Patent, Desk  
 18 OPERATING SYSTEM: Computer  
 19 SOFTWARE: AS-1 (AS-1)  
 20 CURRENT APPLICATION DATA:  
 21 APPLICATION NUMBER: 44-38842  
 22 FILING DATE: 10/1/64  
 23 CLASSIFICATION: 44-38842  
 24 FILING APPLICATION DATA:  
 25 APPLICATION NUMBER:  
 26 FILING DATE:  
 27 ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED  
 28 EXCEPT WHERE SHOWN OTHERWISE  
 29 DATE 10/1/64 BY 104













1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes that proper record-keeping is essential for transparency and accountability, particularly in financial matters. The text outlines various methods for organizing and storing data, including digital databases and physical filing systems. It also mentions the need for regular audits and reviews to ensure the integrity of the information.

2. The second section focuses on the role of communication in achieving organizational goals. It highlights the importance of clear and concise communication channels, both internally and externally. The text discusses the benefits of regular meetings, reports, and updates, as well as the potential pitfalls of poor communication. It encourages the use of technology to facilitate communication and collaboration among team members.

3. The third part of the document addresses the issue of resource management. It discusses the importance of identifying and allocating resources effectively to support the organization's mission. The text provides guidance on how to prioritize tasks and manage budgets, as well as strategies for recruiting and retaining talent. It also touches on the importance of maintaining a healthy work-life balance for employees.

4. The final section discusses the importance of continuous improvement and innovation. It encourages the organization to regularly evaluate its processes and procedures, and to seek out new ways to improve efficiency and effectiveness. The text mentions the importance of staying up-to-date on industry trends and technologies, and the role of research and development in driving growth and innovation.









cell growth stimulation, they can also be used for crystallography, and for other biophysical structural studies.

XX Sequence 2055 bp; 576 A; 472 C; 477 G; 546 T; 9 other;

# Alignment Scores:

Prod. No.: 2550 Length: 2055  
 Score: 5500 Match: 10  
 Percent Similarity: 100.0% Conserved: 1  
 Best Local Similarity: 90.94% Mismatch: 0  
 Query Match: 94.86% Indels: 0  
 Gaps: 0

US-09-667-365-1897 (1-1) x AAS941926 (1-2055)

17 1 IsolytArasSeCreAla86ThrThrAlaLon 11  
 14 841 TATAATGCGCTGCTGATGCGTAAAGAAACTTG 60

# RESULTS

AAS941926

XX AAS941926 standard: cDNA; 2055 bp;

XX AAS941926

XX 15 bp 2055 (1188-2055)

XX Human ch22c2 coding sequence.

XX Human ch22c2: ch22: ch22c2 (checkpoint); cell cycle regulation;  
 XX human cell proliferation; apoptosis; ss;

XX Human sequences.

XX Key: Identical/2nucleotides

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

Score: 5500 Match: 10  
 Percent Similarity: 100.0% Conserved: 1  
 Best Local Similarity: 90.94% Mismatch: 0  
 Query Match: 94.86% Indels: 0  
 Gaps: 0

US-09-667-365-1897 (1-1) x AAS941926 (1-2055)

17 1 IsolytArasSeCreAla86ThrThrAlaLon 11

14 841 TATAATGCGCTGCTGATGCGTAAAGAAACTTG 60

# RESULTS

AAS941926

XX AAS941926 standard: cDNA; 2055 bp;

XX AAS941926

XX 15 bp 2002 (1188-2002)

XX cDNA isolated from human fibroblast cell line A431.

XX Human chromosome mapping: gene mapping; gene mapping; gene mapping;  
 XX food supplement; medical malpractice; diagnostic; genetic disorder; ss;

XX Human sequences.

XX W220 (1997) A2.

XX 1188-2002

XX 2055-2002; 2001W; 2500-2002

XX 41 MA; 2000; 2000US; 0540211

XX 25 MA; 2000; 2000US; 0540211

XX (HVS) 3 HVS; 1N

XX Human cDNA; 1188-2002

XX W220 (1997) A2.

XX 1188-2002

XX 2055-2002; 2001W; 2500-2002

XX 41 MA; 2000; 2000US; 0540211

XX 25 MA; 2000; 2000US; 0540211

XX (HVS) 3 HVS; 1N

XX Human cDNA; 1188-2002

XX W220 (1997) A2.

XX 1188-2002

XX 2055-2002; 2001W; 2500-2002

XX 41 MA; 2000; 2000US; 0540211

XX 25 MA; 2000; 2000US; 0540211

XX (HVS) 3 HVS; 1N

XX Human cDNA; 1188-2002

XX W220 (1997) A2.

XX 1188-2002

XX 2055-2002; 2001W; 2500-2002

XX 41 MA; 2000; 2000US; 0540211

XX 25 MA; 2000; 2000US; 0540211

XX (HVS) 3 HVS; 1N

XX Human cDNA; 1188-2002

XX W220 (1997) A2.

XX 1188-2002

XX 2055-2002; 2001W; 2500-2002

XX 41 MA; 2000; 2000US; 0540211

XX 25 MA; 2000; 2000US; 0540211

XX (HVS) 3 HVS; 1N

XX Human cDNA; 1188-2002

XX W220 (1997) A2.

XX 1188-2002

XX 2055-2002; 2001W; 2500-2002

XX 41 MA; 2000; 2000US; 0540211

XX 25 MA; 2000; 2000US; 0540211

XX (HVS) 3 HVS; 1N

XX Human cDNA; 1188-2002

XX W220 (1997) A2.

XX 1188-2002

cell growth stimulation, they can also be used for crystallography, and for other biophysical structural studies.

XX Sequence 2055 bp; 576 A; 472 C; 477 G; 546 T; 9 other;

# Alignment Scores:

Prod. No.: 2550 Length: 2055  
 Score: 5500 Match: 10  
 Percent Similarity: 100.0% Conserved: 1  
 Best Local Similarity: 90.94% Mismatch: 0  
 Query Match: 94.86% Indels: 0  
 Gaps: 0

US-09-667-365-1897 (1-1) x AAS941926 (1-2055)

17 1 IsolytArasSeCreAla86ThrThrAlaLon 11  
 14 841 TATAATGCGCTGCTGATGCGTAAAGAAACTTG 60

# RESULTS

AAS941926

XX AAS941926 standard: cDNA; 2055 bp;

XX AAS941926

XX 15 bp 2055 (1188-2055)

XX Human ch22c2 coding sequence.

XX Human ch22c2: ch22: ch22c2 (checkpoint); cell cycle regulation;  
 XX human cell proliferation; apoptosis; ss;

XX Human sequences.

XX Key: Identical/2nucleotides

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

cell growth stimulation, they can also be used for crystallography, and for other biophysical structural studies.

XX Sequence 2055 bp; 576 A; 472 C; 477 G; 546 T; 9 other;

# Alignment Scores:

Prod. No.: 2550 Length: 2055  
 Score: 5500 Match: 10  
 Percent Similarity: 100.0% Conserved: 1  
 Best Local Similarity: 90.94% Mismatch: 0  
 Query Match: 94.86% Indels: 0  
 Gaps: 0

US-09-667-365-1897 (1-1) x AAS941926 (1-2055)

17 1 IsolytArasSeCreAla86ThrThrAlaLon 11  
 14 841 TATAATGCGCTGCTGATGCGTAAAGAAACTTG 60

# RESULTS

AAS941926

XX AAS941926 standard: cDNA; 2055 bp;

XX AAS941926

XX 15 bp 2055 (1188-2055)

XX Human ch22c2 coding sequence.

XX Human ch22c2: ch22: ch22c2 (checkpoint); cell cycle regulation;  
 XX human cell proliferation; apoptosis; ss;

XX Human sequences.

XX Key: Identical/2nucleotides

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500

cell growth stimulation, they can also be used for crystallography, and for other biophysical structural studies.

XX Sequence 2055 bp; 576 A; 472 C; 477 G; 546 T; 9 other;

# Alignment Scores:

Prod. No.: 2550 Length: 2055  
 Score: 5500 Match: 10  
 Percent Similarity: 100.0% Conserved: 1  
 Best Local Similarity: 90.94% Mismatch: 0  
 Query Match: 94.86% Indels: 0  
 Gaps: 0

US-09-667-365-1897 (1-1) x AAS941926 (1-2055)

17 1 IsolytArasSeCreAla86ThrThrAlaLon 11  
 14 841 TATAATGCGCTGCTGATGCGTAAAGAAACTTG 60

# RESULTS

AAS941926

XX AAS941926 standard: cDNA; 2055 bp;

XX AAS941926

XX 15 bp 2055 (1188-2055)

XX Human ch22c2 coding sequence.

XX Human ch22c2: ch22: ch22c2 (checkpoint); cell cycle regulation;  
 XX human cell proliferation; apoptosis; ss;

XX Human sequences.

XX Key: Identical/2nucleotides

XX 2550/5500

XX 2550/5500

XX 2550/5500

XX 2550/5500



[illegible]



















00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000

00000000





[illegible][illegible]

1. *Introduction*  
 2. *Methodology*  
 3. *Results*  
 4. *Discussion*  
 5. *Conclusion*  
 6. *Acknowledgements*  
 7. *References*  
 8. *Appendix*  
 9. *Notes*  
 10. *Tables*  
 11. *Figures*  
 12. *Supplementary Materials*  
 13. *Correspondence*  
 14. *Conflict of Interest*  
 15. *Author Contributions*  
 16. *Disclaimer*  
 17. *Copyright*  
 18. *Open Access*  
 19. *Keywords*  
 20. *Subject Terms*  
 21. *Abbreviations*  
 22. *References*  
 23. *Appendix*  
 24. *Notes*  
 25. *Tables*  
 26. *Figures*  
 27. *Supplementary Materials*  
 28. *Correspondence*  
 29. *Conflict of Interest*  
 30. *Author Contributions*  
 31. *Disclaimer*  
 32. *Copyright*  
 33. *Open Access*  
 34. *Keywords*  
 35. *Subject Terms*  
 36. *Abbreviations*  
 37. *References*  
 38. *Appendix*  
 39. *Notes*  
 40. *Tables*  
 41. *Figures*  
 42. *Supplementary Materials*  
 43. *Correspondence*  
 44. *Conflict of Interest*  
 45. *Author Contributions*  
 46. *Disclaimer*  
 47. *Copyright*  
 48. *Open Access*  
 49. *Keywords*  
 50. *Subject Terms*  
 51. *Abbreviations*  
 52. *References*  
 53. *Appendix*  
 54. *Notes*  
 55. *Tables*  
 56. *Figures*  
 57. *Supplementary Materials*  
 58. *Correspondence*  
 59. *Conflict of Interest*  
 60. *Author Contributions*  
 61. *Disclaimer*  
 62. *Copyright*  
 63. *Open Access*  
 64. *Keywords*  
 65. *Subject Terms*  
 66. *Abbreviations*  
 67. *References*  
 68. *Appendix*  
 69. *Notes*  
 70. *Tables*  
 71. *Figures*  
 72. *Supplementary Materials*  
 73. *Correspondence*  
 74. *Conflict of Interest*  
 75. *Author Contributions*  
 76. *Disclaimer*  
 77. *Copyright*  
 78. *Open Access*  
 79. *Keywords*  
 80. *Subject Terms*  
 81. *Abbreviations*  
 82. *References*  
 83. *Appendix*  
 84. *Notes*  
 85. *Tables*  
 86. *Figures*  
 87. *Supplementary Materials*  
 88. *Correspondence*  
 89. *Conflict of Interest*  
 90. *Author Contributions*  
 91. *Disclaimer*  
 92. *Copyright*  
 93. *Open Access*  
 94. *Keywords*  
 95. *Subject Terms*  
 96. *Abbreviations*  
 97. *References*  
 98. *Appendix*  
 99. *Notes*  
 100. *Tables*  
 101. *Figures*  
 102. *Supplementary Materials*  
 103. *Correspondence*  
 104. *Conflict of Interest*  
 105. *Author Contributions*  
 106. *Disclaimer*  
 107. *Copyright*  
 108. *Open Access*  
 109. *Keywords*  
 110. *Subject Terms*  
 111. *Abbreviations*  
 112. *References*  
 113. *Appendix*  
 114. *Notes*  
 115. *Tables*  
 116. *Figures*  
 117. *Supplementary Materials*  
 118. *Correspondence*  
 119. *Conflict of Interest*  
 120. *Author Contributions*  
 121. *Disclaimer*  
 122. *Copyright*  
 123. *Open Access*  
 124. *Keywords*  
 125. *Subject Terms*  
 126. *Abbreviations*  
 127. *References*  
 128. *Appendix*  
 129. *Notes*  
 130. *Tables*  
 131. *Figures*  
 132. *Supplementary Materials*  
 133. *Correspondence*  
 134. *Conflict of Interest*  
 135. *Author Contributions*  
 136. *Disclaimer*  
 137. *Copyright*  
 138. *Open Access*  
 139. *Keywords*  
 140. *Subject Terms*  
 141. *Abbreviations*  
 142. *References*  
 143. *Appendix*  
 144. *Notes*  
 145. *Tables*  
 146. *Figures*  
 147. *Supplementary Materials*  
 148. *Correspondence*  
 149. *Conflict of Interest*  
 150. *Author Contributions*  
 151. *Disclaimer*  
 152. *Copyright*  
 153. *Open Access*  
 154. *Keywords*  
 155. *Subject Terms*  
 156. *Abbreviations*  
 157. *References*  
 158. *Appendix*  
 159. *Notes*  
 160. *Tables*  
 161. *Figures*  
 162. *Supplementary Materials*  
 163. *Correspondence*  
 164. *Conflict of Interest*  
 165. *Author Contributions*  
 166. *Disclaimer*  
 167. *Copyright*  
 168. *Open Access*  
 169. *Keywords*  
 170. *Subject Terms*  
 171. *Abbreviations*  
 172. *References*  
 173. *Appendix*  
 174. *Notes*  
 175. *Tables*  
 176. *Figures*  
 177. *Supplementary Materials*  
 178. *Correspondence*  
 179. *Conflict of Interest*  
 180. *Author Contributions*  
 181. *Disclaimer*  
 182. *Copyright*  
 183. *Open Access*  
 184. *Keywords*  
 185. *Subject Terms*  
 186. *Abbreviations*  
 187. *References*  
 188. *Appendix*  
 189. *Notes*  
 190. *Tables*  
 191. *Figures*  
 192. *Supplementary Materials*  
 193. *Correspondence*  
 194. *Conflict of Interest*  
 195. *Author Contributions*  
 196. *Disclaimer*  
 197. *Copyright*  
 198. *Open Access*  
 199. *Keywords*  
 200. *Subject Terms*  
 201. *Abbreviations*  
 202. *References*  
 203. *Appendix*  
 204. *Notes*  
 205. *Tables*  
 206. *Figures*  
 207. *Supplementary Materials*  
 208. *Correspondence*  
 209. *Conflict of Interest*  
 210. *Author Contributions*  
 211. *Disclaimer*  
 212. *Copyright*  
 213. *Open Access*  
 214. *Keywords*  
 215. *Subject Terms*  
 216. *Abbreviations*  
 217. *References*  
 218. *Appendix*  
 219. *Notes*  
 220. *Tables*  
 221. *Figures*  
 222. *Supplementary Materials*  
 223. *Correspondence*  
 224. *Conflict of Interest*  
 225. *Author Contributions*  
 226. *Disclaimer*  
 227. *Copyright*  
 228. *Open Access*  
 229. *Keywords*  
 230. *Subject Terms*  
 231. *Abbreviations*  
 232. *References*  
 233. *Appendix*  
 234. *Notes*  
 235. *Tables*  
 236. *Figures*  
 237. *Supplementary Materials*  
 238. *Correspondence*  
 239. *Conflict of Interest*  
 240. *Author Contributions*  
 241. *Disclaimer*  
 242. *Copyright*  
 243. *Open Access*  
 244. *Keywords*  
 245. *Subject Terms*  
 246. *Abbreviations*  
 247. *References*  
 248. *Appendix*  
 249. *Notes*  
 250

•

Figure 1. The effect of the number of trials on the number of correct responses. The number of correct responses was significantly higher than the number of incorrect responses in all conditions. The number of correct responses was significantly higher than the number of incorrect responses in all conditions. The number of correct responses was significantly higher than the number of incorrect responses in all conditions.

[illegible]

100

[illegible][illegible]

•

1

•

•

•

•

•

• • •

1

• •

● ●

●

10

\_\_\_\_\_





















1000  
 1001  
 1002  
 1003  
 1004  
 1005  
 1006  
 1007  
 1008  
 1009  
 1010  
 1011  
 1012  
 1013  
 1014  
 1015  
 1016  
 1017  
 1018  
 1019  
 1020  
 1021  
 1022  
 1023  
 1024  
 1025  
 1026  
 1027  
 1028  
 1029  
 1030  
 1031  
 1032  
 1033  
 1034  
 1035  
 1036  
 1037  
 1038  
 1039  
 1040  
 1041  
 1042  
 1043  
 1044  
 1045  
 1046  
 1047  
 1048  
 1049  
 1050  
 1051  
 1052  
 1053  
 1054  
 1055  
 1056  
 1057  
 1058  
 1059  
 1060  
 1061  
 1062  
 1063  
 1064  
 1065  
 1066  
 1067  
 1068  
 1069  
 1070  
 1071  
 1072  
 1073  
 1074  
 1075  
 1076  
 1077  
 1078  
 1079  
 1080  
 1081  
 1082  
 1083  
 1084  
 1085  
 1086  
 1087  
 1088  
 1089  
 1090  
 1091  
 1092  
 1093  
 1094  
 1095  
 1096  
 1097  
 1098  
 1099  
 1100  
 1101  
 1102  
 1103  
 1104  
 1105  
 1106  
 1107  
 1108  
 1109  
 1110  
 1111  
 1112  
 1113  
 1114  
 1115  
 1116  
 1117  
 1118  
 1119  
 1120  
 1121  
 1122  
 1123  
 1124  
 1125  
 1126  
 1127  
 1128  
 1129  
 1130  
 1131  
 1132  
 1133  
 1134  
 1135  
 1136  
 1137  
 1138  
 1139  
 1140  
 1141  
 1142  
 1143  
 1144  
 1145  
 1146  
 1147  
 1148  
 1149  
 1150  
 1151  
 1152  
 1153  
 1154  
 1155  
 1156  
 1157  
 1158  
 1159  
 1160  
 1161  
 1162  
 1163  
 1164  
 1165  
 1166  
 1167  
 1168  
 1169  
 1170  
 1171  
 1172  
 1173  
 1174  
 1175  
 1176  
 1177  
 1178  
 1179  
 1180  
 1181  
 1182  
 1183  
 1184  
 1185  
 1186  
 1187  
 1188  
 1189  
 1190  
 1191  
 1192  
 1193  
 1194  
 1195  
 1196  
 1197  
 1198  
 1199  
 1200  
 1201  
 1202  
 1203  
 1204  
 1205  
 1206  
 1207  
 1208  
 1209  
 1210  
 1211  
 1212  
 1213  
 1214  
 1215  
 1216  
 1217  
 1218  
 1219  
 1220  
 1221  
 1222  
 1223  
 1224  
 1225  
 1226  
 1227  
 1228  
 1229  
 1230  
 1231  
 1232  
 1233  
 1234  
 1235  
 1236  
 1237  
 1238  
 1239  
 1240  
 1241  
 1242  
 1243  
 1244  
 1245  
 1246  
 1247  
 1248  
 1249  
 1250  
 1251  
 1252  
 1253  
 1254  
 1255  
 1256  
 1257  
 1258  
 1259  
 1260  
 1261  
 1262  
 1263  
 1264  
 1265  
 1266  
 1267  
 1268  
 1269  
 1270  
 1271  
 1272  
 1273  
 1274  
 1275  
 1276  
 1277  
 1278  
 1279  
 1280  
 1281  
 1282  
 1283  
 1284  
 1285  
 1286  
 1287  
 1288  
 1289  
 1290  
 1291  
 1292  
 1293  
 1294  
 1295  
 1296  
 1297  
 1298  
 1299  
 1300  
 1301  
 1302  
 1303  
 1304  
 1305  
 1306  
 1307  
 1308  
 1309  
 1310  
 1311  
 1312  
 1313  
 1314  
 1315  
 1316  
 1317  
 1318  
 1319  
 1320  
 1321  
 1322  
 1323  
 1324  
 1325  
 1326  
 1327  
 1328  
 1329  
 1330  
 1331  
 1332  
 1333  
 1334  
 1335  
 1336  
 1337  
 1338  
 1339  
 1340  
 1341  
 1342  
 1343  
 1344  
 1345  
 1346  
 1347  
 1348  
 1349  
 1350  
 1351  
 1352  
 1353  
 1354  
 1355  
 1356  
 1357  
 1358  
 1359  
 1360  
 1361  
 1362  
 1363  
 1364  
 1365  
 1366  
 1367  
 1368  
 1369  
 1370  
 1371  
 1372  
 1373  
 1374  
 1375  
 1376  
 1377  
 1378  
 1379  
 1380  
 1381  
 1382  
 1383  
 1384  
 1385  
 1386  
 1387  
 1388  
 1389  
 1390  
 1391  
 1392  
 1393  
 1394  
 1395  
 1396  
 1397  
 1398  
 1399  
 1400  
 1401  
 1402  
 1403  
 1404  
 1405  
 1406  
 1407  
 1408  
 1409  
 1410  
 1411  
 1412  
 1413  
 1414  
 1415  
 1416  
 1417  
 1418  
 1419  
 1420  
 1421  
 1422  
 1423  
 1424  
 1425  
 1426  
 1427  
 1428  
 1429  
 1430  
 1431  
 1432  
 1433  
 1434  
 1435  
 1436  
 1437  
 1438  
 1439  
 1440  
 1441  
 1442  
 1443  
 1444  
 1445  
 1446  
 1447  
 1448  
 1449  
 1450  
 1451  
 1452  
 1453  
 1454  
 1455  
 1456  
 1457  
 1458  
 1459  
 1460  
 1461  
 1462  
 1463  
 1464  
 1465  
 1466  
 1467  
 1468  
 1469  
 1470  
 1471  
 1472  
 1473  
 1474  
 1475  
 1476  
 1477  
 1478  
 1479  
 1480  
 1481  
 1482  
 1483  
 1484  
 1485  
 1486  
 1487  
 1488  
 1489  
 1490  
 1491  
 1492  
 1493  
 1494  
 1495  
 1496  
 1497  
 1498  
 1499  
 1500  
 1501  
 1502  
 1503  
 1504  
 1505  
 1506  
 1507  
 1508  
 1509  
 1510  
 1511  
 1512  
 1513  
 1514  
 1515  
 1516  
 1517  
 1518  
 1519  
 1520  
 1521  
 1522  
 1523  
 1524  
 1525  
 1526  
 1527  
 1528  
 1529  
 1530  
 1531  
 1532  
 1533  
 1534  
 1535  
 1536  
 1537  
 1538  
 1539  
 1540  
 1541  
 1542  
 1543  
 1544  
 1545  
 1546  
 1547  
 1548  
 1549  
 1550  
 1551  
 1552  
 1553  
 1554  
 1555  
 1556  
 1557  
 1558  
 1559  
 1560  
 1561  
 1562  
 1563  
 1564  
 1565  
 1566  
 1567  
 1568  
 1569  
 1570  
 1571  
 1572  
 1573  
 1574  
 1575  
 1576  
 1577  
 1578  
 1579  
 1580  
 1581  
 1582  
 1583  
 1584  
 1585  
 1586  
 1587  
 1588  
 1589  
 1590  
 1591  
 1592  
 1593  
 1594  
 1595  
 1596  
 1597  
 1598  
 1599  
 1600  
 1601  
 1602  
 1603  
 1604  
 1605  
 1606  
 1607  
 1608  
 1609  
 1610  
 1611  
 1612  
 1613  
 1614  
 1615  
 1616  
 1617  
 1618  
 1619  
 1620  
 1621  
 1622  
 1623  
 1624  
 1625  
 1626  
 1627  
 1628  
 1629  
 1630  
 1631  
 1632  
 1633  
 1634  
 1635  
 1636  
 1637  
 1638  
 1639  
 1640  
 1641  
 1642  
 1643  
 1644  
 1645  
 1646  
 1647  
 1648  
 1649  
 1650  
 1651  
 1652  
 1653  
 1654  
 1655  
 1656  
 1657  
 1658  
 1659  
 1660  
 1661  
 1662  
 1663  
 1664  
 1665  
 1666  
 1667  
 1668  
 1669  
 1670  
 1671  
 1672  
 1673  
 1674  
 1675  
 1676  
 1677  
 1678  
 1679  
 1680  
 1681  
 1682  
 1683  
 1684  
 1685  
 1686  
 1687  
 1688  
 1689  
 1690  
 1691  
 1692  
 1693  
 1694  
 1695  
 1696  
 1697  
 1698  
 1699  
 1700  
 1701  
 1702  
 1703  
 1704  
 1705  
 1706  
 1707  
 1708  
 1709  
 1710  
 1711  
 1712  
 1713  
 1714  
 1715  
 1716  
 1717  
 1718  
 1719  
 1720  
 1721  
 1722  
 1723  
 1724  
 1725  
 1726  
 1727  
 1728  
 1729  
 1730  
 1731  
 1732  
 1733  
 1734  
 1735  
 1736  
 1737  
 1738  
 1739  
 1740  
 1741  
 1742  
 1743  
 1744  
 1745  
 1746  
 1747  
 1748  
 1749  
 1750  
 1751  
 1752  
 1753  
 1754  
 1755  
 1756  
 1757  
 1758  
 1759  
 1760  
 1761  
 1762  
 1763  
 1764  
 1765  
 1766  
 1767  
 1768  
 1769  
 1770  
 1771  
 1772  
 1773  
 1774  
 1775  
 1776  
 1777  
 1778  
 1779  
 1780  
 1781  
 1782  
 1783  
 1784  
 1785  
 1786  
 1787  
 1788  
 1789  
 1790  
 1791  
 1792  
 1793  
 1794  
 1795  
 1796  
 1797  
 1798  
 1799  
 1800  
 1801  
 1802  
 1803  
 1804  
 1805  
 1806  
 1807  
 1808  
 1809  
 1810  
 1811  
 1812  
 1813  
 1814  
 1815  
 1816  
 1817  
 1818  
 1819  
 1820  
 1821  
 1822  
 1823  
 1824  
 1825  
 1826  
 1827  
 1828  
 1829  
 1830  
 1831  
 1832  
 1833  
 1834  
 1835  
 1836  
 1837  
 1838  
 1839  
 1840  
 1841  
 1842  
 1843  
 1844  
 1845  
 1846  
 1847  
 1848  
 1849  
 1850  
 1851  
 1852  
 1853  
 1854  
 1855  
 1856  
 1857  
 1858  
 1859  
 1860  
 1861  
 1862  
 1863  
 1864  
 1865  
 1866  
 1867  
 1868  
 1869  
 1870  
 1871  
 1872  
 1873  
 1874  
 1875  
 1876  
 1877  
 1878  
 1879  
 1880  
 1881  
 1882  
 1883  
 1884  
 1885  
 1886  
 1887  
 1888  
 1889  
 1890  
 1891  
 1892  
 1893  
 1894  
 1895  
 1896  
 1897  
 1898  
 1899  
 1900  
 1901  
 1902  
 1903  
 1904  
 1905  
 1906  
 1907  
 1908  
 1909  
 1910  
 1911  
 1912  
 1913  
 1914  
 1915  
 1916  
 1917  
 1918  
 1919  
 1920  
 1921  
 1922  
 1923  
 1924  
 1925  
 1926  
 1927  
 1928  
 1929  
 1930  
 1931  
 1932  
 1933  
 1934  
 1935  
 1936  
 1937  
 1938  
 1939  
 1940  
 1941  
 1942  
 1943  
 1944  
 1945  
 1946  
 1947  
 1948  
 1949  
 1950  
 1951  
 1952  
 1953  
 1954  
 1955  
 1956  
 1957  
 1958  
 1959  
 1960  
 1961  
 1962  
 1963  
 1964  
 1965  
 1966  
 1967  
 1968  
 1969  
 1970  
 1971  
 1972  
 1973  
 1974  
 1975  
 1976  
 1977  
 1978  
 1979  
 1980  
 1981  
 1982  
 1983  
 1984  
 1985  
 1986  
 1987  
 1988  
 1989  
 1990  
 1991  
 1992  
 1993  
 1994  
 1995  
 1996  
 1997  
 1998  
 1999  
 2000  
 2001  
 2002  
 2003  
 2004  
 2005  
 2006  
 2007  
 2008  
 2009  
 2010  
 2011  
 2012  
 2013  
 2014  
 2015  
 2016  
 2017  
 2018  
 2019  
 2020  
 2021  
 2022  
 2023  
 2024  
 2025  
 2026  
 2027  
 2028  
 2029  
 2030  
 2031  
 2032  
 2033  
 2034  
 2035  
 2036  
 2037  
 2038  
 2039  
 2040  
 2041  
 2042  
 2043  
 2044  
 2045  
 2046  
 2047  
 2048  
 2049  
 2050  
 2051  
 2052  
 2053  
 2054  
 2055  
 2056  
 2057  
 2058  
 2059  
 2060  
 2061  
 2062  
 2063  
 2064  
 2065  
 2066  
 2067  
 2068  
 2069  
 2070  
 2071  
 2072  
 2073  
 2074  
 2075  
 2076  
 2077  
 2078  
 2079  
 2080  
 2081  
 2082  
 2083  
 2084  
 2085  
 2086  
 2087  
 2088  
 2089  
 2090  
 2091  
 2092  
 2093  
 2094  
 2095  
 2096  
 2097  
 2098  
 2099  
 2100  
 2101  
 2102  
 2103  
 2104  
 2105  
 2106  
 2107  
 2108  
 2109  
 2110  
 2111  
 2112  
 2113  
 2114  
 2115  
 2116  
 2117  
 2118  
 2119  
 2120  
 2121  
 2122  
 2123  
 2124  
 2125  
 2126  
 2127  
 2128  
 2129  
 2130  
 2131  
 2132  
 2133  
 2134  
 2135  
 2136  
 2137  
 2138  
 2139  
 2140  
 2141  
 2142  
 2143  
 2144  
 2145  
 2146  
 2147  
 2148  
 2149  
 2150  
 2151  
 2152  
 2153  
 2154  
 2155  
 2156  
 2157  
 2158  
 2159  
 2160  
 2161  
 2162  
 2163  
 2164  
 2165  
 2166  
 2167  
 2168  
 2169  
 2170  
 2171  
 2172  
 2173  
 2174  
 2175  
 2176  
 2177  
 2178  
 2179  
 2180  
 2181  
 2182  
 2183  
 2184  
 2185  
 2186  
 2187  
 2188  
 2189  
 2190  
 2191  
 2192  
 2193  
 2194  
 2195  
 2196  
 2197  
 2198  
 2199  
 2200  
 2201  
 2202  
 2203  
 2204  
 2205  
 2206  
 2207  
 2208  
 2209  
 2210  
 2211  
 2212  
 2213  
 2214  
 2215  
 2216  
 2217  
 2218  
 2219  
 2220  
 2221  
 2222  
 2223  
 2224  
 2225  
 2226  
 2227  
 2228  
 2229  
 2230  
 2231  
 2232  
 2233  
 2234  
 2235  
 2236  
 2237  
 2238  
 2239  
 2240  
 2241  
 2242  
 2243  
 2244  
 2245  
 2246  
 2247  
 2248  
 2249  
 2250  
 2251  
 2252  
 2253  
 2254  
 2255  
 2256  
 2257  
 2258  
 2259  
 2260  
 2261  
 2262  
 2263  
 2264  
 2265  
 2266  
 2267  
 2268  
 2269  
 2270  
 2271  
 2272  
 2273  
 2274  
 2275  
 2276  
 2277  
 2278  
 2279  
 2280  
 2281  
 2282  
 2283  
 2284  
 2285  
 2286  
 2287  
 2288  
 2289  
 2290  
 2291  
 2292  
 2293  
 2294  
 2295  
 2296  
 2297  
 2298  
 2299  
 2300  
 2301  
 2302  
 2303  
 2304  
 2305  
 2306  
 2307  
 2308  
 2309  
 2310  
 2311  
 2312  
 2313  
 2314  
 2315  
 2316  
 2317  
 2318  
 2319  
 2320  
 2321  
 2322  
 2323  
 2324  
 2325  
 2326  
 2327  
 2328  
 2329  
 2330  
 2331  
 2332  
 2333  
 2334  
 2335  
 2336  
 2337  
 2338  
 2339  
 2340  
 2341  
 2342  
 2343  
 2344  
 2345  
 2346  
 2347  
 2348  
 2349  
 2350  
 2351  
 235

1. OTHER INFORMATION: N. Xao equals any of the naturally occurring L-amino acids.  
2. NAME/KEY: SILE  
3. LOCATION: (66)  
4. OTHER INFORMATION: Xao equals any of the naturally occurring L-amino acids.  
US 09 667 365 1897

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44

Query Match: 65.9%, Score: 32, ID: 10, Length: 406,  
Best Local Similarity: 65.9%, Prod. No.: 29  
Matches: 6, Conservation: 1, Mismatches: 0, Gaps: 0  
27 1 YPSDAM 7  
13 20 YPSDAL 44



1. 80.00. No. 10476  
 2. LENGTH: 474  
 3. TYPE: PR1  
 4. ORGANISM: Enterococcus faecalis  
 02-09-01-242-10476

YP017 Match: 90.20% Score: 527 DB: 1.3-100.0h 4743  
 Best Local Similarity: 60.00% Prod: No. 2.100-124  
 Matches: 67 Conserved: 1 Mismatches: 3 Indels: 0 Gaps: 0

17 2 YPSIAMENI 11  
 103 111  
 14 434 YPSURIPANI 443

Search completed: October 31, 2002 23:26:21  
 CPU time: 1.25 sec



[illegible][illegible]







11 Nov 2002 10:00 AM - 10:00 AM - 10:00 AM - 10:00 AM

11 Nov 2002 10:00 AM - 10:00 AM - 10:00 AM - 10:00 AM

11 Nov 2002 10:00 AM - 10:00 AM - 10:00 AM - 10:00 AM

11 Nov 2002 10:00 AM - 10:00 AM - 10:00 AM - 10:00 AM

11 Nov 2002 10:00 AM - 10:00 AM - 10:00 AM - 10:00 AM









1 CITY: Kalamazoo  
 2 STATE: MI  
 3 COUNTRY: USA  
 4 ZIP: 49001  
 5 MODIFIER FEASIBLE FORM:  
 6 MEDIUM TYPE: Floppy disk  
 7 MODIFIER: IBM PC compatible  
 8 OPERATING SYSTEM: pc/compat  
 9 SOFTWARE: Patent in Release #1.0, Version #1.25  
 10 APPLICATION NUMBER: 05/08/048,816  
 11 FILING DATE:  
 12 CLASSIFICATION: 4.5  
 13 ALL PREV/AGMT INFORMATION:  
 14 NAME: Woodcock, Thomas A.  
 15 PESTIFICATION NUMBER: 45,004  
 16 TELECOMMUNICATION INFORMATION:  
 17 TELEPHONE: 616 833 7914  
 18 TELEFAX: 616 833 6897  
 19 INFORMATION FOR SEQ ID NO: 4:  
 20 SEQUENCE CHARACTERISTICS:  
 21 LENGTH: 265 amino acids  
 22 TYPE: amino acid  
 23 STRANDEDNESS: single  
 24 TOPOLOGY: linear  
 25 MODIFIER TYPE: peptide  
 26 HYDROPHILIC: No  
 27 ANTI-CHARGE: No  
 28 US-08-048-810-4

Query Match: 62.1% Score 307 ID: 4 Length 265  
 Best Local Similarity: 75.0% Prod. No. 43  
 Matches: 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

29 1 LYSRAMP R  
 30 1 L L L L L  
 31 4 LYSRAMP L

RESULT 1  
 1 Sequence 14, Application US/08048810  
 2 Patent No. 6074851  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Deibel, Jiro M. E.  
 5 ADDRESS: Yon, A. W.  
 6 ADDRESS: Kalamazoo, MI  
 7 TITLE OF INVENTION: Catalyst for Matrix Polymerization  
 8 TITLE OF INVENTION: Like Activity  
 9 NUMBER OF INVENTION: 45  
 10 PESTIFICATION NUMBER: 45,004  
 11 TELECOMMUNICATION INFORMATION:  
 12 ADDRESS: Kalamazoo, MI  
 13 TELEFAX: 616 833 6897  
 14 INFORMATION FOR SEQ ID NO: 14:  
 15 SEQUENCE CHARACTERISTICS:  
 16 LENGTH: 265 amino acids  
 17 TYPE: amino acid  
 18 STRANDEDNESS: single  
 19 TOPOLOGY: linear  
 20 MODIFIER TYPE: peptide  
 21 HYDROPHILIC: No  
 22 ANTI-CHARGE: No  
 23 US-08-048-810-14  
 24 Query Match: 62.1% Score 307 ID: 4 Length 265  
 25 Best Local Similarity: 75.0% Prod. No. 43  
 26 Matches: 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

27 1 LYSRAMP R  
 28 1 L L L L L  
 29 4 LYSRAMP L

1 SEQUENCE CHARACTERISTICS:  
 2 LENGTH: 265 amino acids  
 3 TYPE: amino acid  
 4 STRANDEDNESS: single  
 5 TOPOLOGY: linear  
 6 MODIFIER TYPE: peptide  
 7 HYDROPHILIC: No  
 8 ANTI-CHARGE: No  
 9 US-08-048-810-14  
 10 Query Match: 62.1% Score 307 ID: 4 Length 265  
 11 Best Local Similarity: 75.0% Prod. No. 43  
 12 Matches: 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

29 1 LYSRAMP R  
 30 1 L L L L L  
 31 4 LYSRAMP L

RESULT 10  
 1 Sequence 14, Application US/08048810  
 2 Patent No. 6074851  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Deibel, Jiro M. E.  
 5 ADDRESS: Yon, A. W.  
 6 ADDRESS: Kalamazoo, MI  
 7 TITLE OF INVENTION: Catalyst for Matrix Polymerization  
 8 TITLE OF INVENTION: Like Activity  
 9 NUMBER OF INVENTION: 45  
 10 PESTIFICATION NUMBER: 45,004  
 11 TELECOMMUNICATION INFORMATION:  
 12 ADDRESS: Kalamazoo, MI  
 13 TELEFAX: 616 833 6897  
 14 INFORMATION FOR SEQ ID NO: 10:  
 15 SEQUENCE CHARACTERISTICS:  
 16 LENGTH: 265 amino acids  
 17 TYPE: amino acid  
 18 STRANDEDNESS: single  
 19 TOPOLOGY: linear  
 20 MODIFIER TYPE: peptide  
 21 HYDROPHILIC: No  
 22 ANTI-CHARGE: No  
 23 US-08-048-810-10  
 24 Query Match: 62.1% Score 307 ID: 4 Length 265  
 25 Best Local Similarity: 75.0% Prod. No. 43  
 26 Matches: 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

29 1 LYSRAMP R  
 30 1 L L L L L  
 31 4 LYSRAMP L

RESULT 11  
 1 Sequence 14, Application US/08048810  
 2 Patent No. 6074851  
 3 GENERAL INFORMATION:  
 4 APPLICANT: Deibel, Jiro M. E.  
 5 ADDRESS: Yon, A. W.  
 6 ADDRESS: Kalamazoo, MI  
 7 TITLE OF INVENTION: Catalyst for Matrix Polymerization  
 8 TITLE OF INVENTION: Like Activity  
 9 NUMBER OF INVENTION: 45  
 10 PESTIFICATION NUMBER: 45,004  
 11 TELECOMMUNICATION INFORMATION:  
 12 ADDRESS: Kalamazoo, MI  
 13 TELEFAX: 616 833 6897  
 14 INFORMATION FOR SEQ ID NO: 11:  
 15 SEQUENCE CHARACTERISTICS:  
 16 LENGTH: 265 amino acids  
 17 TYPE: amino acid  
 18 STRANDEDNESS: single  
 19 TOPOLOGY: linear  
 20 MODIFIER TYPE: peptide  
 21 HYDROPHILIC: No  
 22 ANTI-CHARGE: No  
 23 US-08-048-810-11  
 24 Query Match: 62.1% Score 307 ID: 4 Length 265  
 25 Best Local Similarity: 75.0% Prod. No. 43  
 26 Matches: 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

29 1 LYSRAMP R  
 30 1 L L L L L  
 31 4 LYSRAMP L



10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

10/11/02

1. AND1 SEQUENCE: N:  
2. 04 04 04 04 04

Query Match: 62.1% Score: 66; Id: 4; Length: 274;  
Best Local Similarity: 75.0%; Prod. No.: 44;  
Matches: 6; Conservative: 2; Mismatches: 0; Indels: 0; Gaps: 0;

1. LTPSPAMP 8  
2. 04 04 04 04 04

#### RESULT 14

US 08 428 415 4

1. Sequence 4: Application US/08428415

2. Patent No.: 443952

3. GENERAL INFORMATION:

4. APPLICANT: Invention, Claitor

5. APPLICANT: Claitor, Claitor

6. APPLICANT: Claitor, Claitor

7. TITLE OF INVENTION: "Amino Acid Sequences and Applications"

8. NUMBER OF INVENTION: 1

9. APPLICANT'S ADDRESS:

10. APPLICANT'S ADDRESS:

11. APPLICANT'S ADDRESS:

12. APPLICANT'S ADDRESS:

13. APPLICANT'S ADDRESS:

14. APPLICANT'S ADDRESS:

15. APPLICANT'S ADDRESS:

16. APPLICANT'S ADDRESS:

17. APPLICANT'S ADDRESS:

18. APPLICANT'S ADDRESS:

19. APPLICANT'S ADDRESS:

20. APPLICANT'S ADDRESS:

21. APPLICANT'S ADDRESS:

22. APPLICANT'S ADDRESS:

23. APPLICANT'S ADDRESS:

24. APPLICANT'S ADDRESS:

25. APPLICANT'S ADDRESS:

26. APPLICANT'S ADDRESS:

27. APPLICANT'S ADDRESS:

28. APPLICANT'S ADDRESS:

29. APPLICANT'S ADDRESS:

30. APPLICANT'S ADDRESS:

31. APPLICANT'S ADDRESS:

32. APPLICANT'S ADDRESS:

33. APPLICANT'S ADDRESS:

34. APPLICANT'S ADDRESS:

35. APPLICANT'S ADDRESS:

36. APPLICANT'S ADDRESS:

37. APPLICANT'S ADDRESS:

38. APPLICANT'S ADDRESS:

39. APPLICANT'S ADDRESS:

40. APPLICANT'S ADDRESS:

41. APPLICANT'S ADDRESS:

42. APPLICANT'S ADDRESS:

43. APPLICANT'S ADDRESS:

44. APPLICANT'S ADDRESS:

45. APPLICANT'S ADDRESS:

46. APPLICANT'S ADDRESS:

47. APPLICANT'S ADDRESS:

48. APPLICANT'S ADDRESS:

49. APPLICANT'S ADDRESS:

50. APPLICANT'S ADDRESS:

51. APPLICANT'S ADDRESS:

52. APPLICANT'S ADDRESS:

53. APPLICANT'S ADDRESS:

54. APPLICANT'S ADDRESS:

55. APPLICANT'S ADDRESS:

56. APPLICANT'S ADDRESS:

57. APPLICANT'S ADDRESS:

58. APPLICANT'S ADDRESS:

59. APPLICANT'S ADDRESS:

60. APPLICANT'S ADDRESS:

61. APPLICANT'S ADDRESS:

62. APPLICANT'S ADDRESS:

63. APPLICANT'S ADDRESS:

64. APPLICANT'S ADDRESS:

65. APPLICANT'S ADDRESS:

66. APPLICANT'S ADDRESS:

67. APPLICANT'S ADDRESS:

68. APPLICANT'S ADDRESS:

69. APPLICANT'S ADDRESS:

70. APPLICANT'S ADDRESS:

71. APPLICANT'S ADDRESS:

72. APPLICANT'S ADDRESS:

73. APPLICANT'S ADDRESS:

74. APPLICANT'S ADDRESS:

75. APPLICANT'S ADDRESS:

76. APPLICANT'S ADDRESS:

77. APPLICANT'S ADDRESS:

78. APPLICANT'S ADDRESS:

79. APPLICANT'S ADDRESS:

80. APPLICANT'S ADDRESS:

81. APPLICANT'S ADDRESS:

82. APPLICANT'S ADDRESS:

83. APPLICANT'S ADDRESS:

84. APPLICANT'S ADDRESS:

85. APPLICANT'S ADDRESS:

86. APPLICANT'S ADDRESS:

87. APPLICANT'S ADDRESS:

88. APPLICANT'S ADDRESS:

89. APPLICANT'S ADDRESS:

90. APPLICANT'S ADDRESS:

91. APPLICANT'S ADDRESS:

92. APPLICANT'S ADDRESS:

93. APPLICANT'S ADDRESS:

94. APPLICANT'S ADDRESS:

95. APPLICANT'S ADDRESS:

96. APPLICANT'S ADDRESS:

97. APPLICANT'S ADDRESS:

98. APPLICANT'S ADDRESS:

99. APPLICANT'S ADDRESS:

100. APPLICANT'S ADDRESS:

101. APPLICANT'S ADDRESS:

102. APPLICANT'S ADDRESS:

103. APPLICANT'S ADDRESS:

104. APPLICANT'S ADDRESS:

105. APPLICANT'S ADDRESS:

106. APPLICANT'S ADDRESS:

107. APPLICANT'S ADDRESS:

108. APPLICANT'S ADDRESS:

109. APPLICANT'S ADDRESS:

110. APPLICANT'S ADDRESS:

111. APPLICANT'S ADDRESS:

112. APPLICANT'S ADDRESS:

113. APPLICANT'S ADDRESS:

114. APPLICANT'S ADDRESS:

115. APPLICANT'S ADDRESS:

116. APPLICANT'S ADDRESS:

117. APPLICANT'S ADDRESS:

118. APPLICANT'S ADDRESS:

119. APPLICANT'S ADDRESS:

120. APPLICANT'S ADDRESS:

121. APPLICANT'S ADDRESS:

122. APPLICANT'S ADDRESS:

123. APPLICANT'S ADDRESS:

124. APPLICANT'S ADDRESS:

125. APPLICANT'S ADDRESS:

126. APPLICANT'S ADDRESS:

127. APPLICANT'S ADDRESS:

128. APPLICANT'S ADDRESS:

129. APPLICANT'S ADDRESS:

130. APPLICANT'S ADDRESS:

131. APPLICANT'S ADDRESS:

132. APPLICANT'S ADDRESS:

133. APPLICANT'S ADDRESS:

134. APPLICANT'S ADDRESS:

135. APPLICANT'S ADDRESS:

136. APPLICANT'S ADDRESS:

137. APPLICANT'S ADDRESS:

138. APPLICANT'S ADDRESS:

139. APPLICANT'S ADDRESS:

140. APPLICANT'S ADDRESS:

141. APPLICANT'S ADDRESS:

142. APPLICANT'S ADDRESS:

143. APPLICANT'S ADDRESS:

144. APPLICANT'S ADDRESS:

145. APPLICANT'S ADDRESS:

146. APPLICANT'S ADDRESS:

147. APPLICANT'S ADDRESS:

148. APPLICANT'S ADDRESS:

149. APPLICANT'S ADDRESS:

150. APPLICANT'S ADDRESS:

151. APPLICANT'S ADDRESS:

152. APPLICANT'S ADDRESS:

153. APPLICANT'S ADDRESS:

154. APPLICANT'S ADDRESS:

155. APPLICANT'S ADDRESS:

156. APPLICANT'S ADDRESS:

157. APPLICANT'S ADDRESS:

158. APPLICANT'S ADDRESS:

159. APPLICANT'S ADDRESS:

160. APPLICANT'S ADDRESS:

161. APPLICANT'S ADDRESS:

162. APPLICANT'S ADDRESS:

163. APPLICANT'S ADDRESS:

164. APPLICANT'S ADDRESS:

165. APPLICANT'S ADDRESS:

166. APPLICANT'S ADDRESS:

167. APPLICANT'S ADDRESS:

168. APPLICANT'S ADDRESS:

169. APPLICANT'S ADDRESS:

170. APPLICANT'S ADDRESS:

171. APPLICANT'S ADDRESS:

172. APPLICANT'S ADDRESS:

173. APPLICANT'S ADDRESS:

174. APPLICANT'S ADDRESS:

175. APPLICANT'S ADDRESS:

176. APPLICANT'S ADDRESS:

177. APPLICANT'S ADDRESS:

178. APPLICANT'S ADDRESS:

179. APPLICANT'S ADDRESS:

180. APPLICANT'S ADDRESS:

181. APPLICANT'S ADDRESS:

182. APPLICANT'S ADDRESS:

183. APPLICANT'S ADDRESS:

184. APPLICANT'S ADDRESS:

185. APPLICANT'S ADDRESS:

186. APPLICANT'S ADDRESS:

187. APPLICANT'S ADDRESS:

188. APPLICANT'S ADDRESS:

189. APPLICANT'S ADDRESS:

190. APPLICANT'S ADDRESS:

191. APPLICANT'S ADDRESS:

192. APPLICANT'S ADDRESS:

193. APPLICANT'S ADDRESS:

194. APPLICANT'S ADDRESS:

195. APPLICANT'S ADDRESS:

196. APPLICANT'S ADDRESS:

197. APPLICANT'S ADDRESS:

198. APPLICANT'S ADDRESS:

199. APPLICANT'S ADDRESS:

200. APPLICANT'S ADDRESS:

201. APPLICANT'S ADDRESS:

202. APPLICANT'S ADDRESS:

203. APPLICANT'S ADDRESS:

204. APPLICANT'S ADDRESS:

205. APPLICANT'S ADDRESS:

206. APPLICANT'S ADDRESS:

207. APPLICANT'S ADDRESS:

208. APPLICANT'S ADDRESS:

209. APPLICANT'S ADDRESS:

210. APPLICANT'S ADDRESS:

211. APPLICANT'S ADDRESS:

212. APPLICANT'S ADDRESS:

213. APPLICANT'S ADDRESS:

214. APPLICANT'S ADDRESS:

215. APPLICANT'S ADDRESS:

216. APPLICANT'S ADDRESS:

217. APPLICANT'S ADDRESS:

218. APPLICANT'S ADDRESS:

219. APPLICANT'S ADDRESS:

220. APPLICANT'S ADDRESS:

221. APPLICANT'S ADDRESS:

222. APPLICANT'S ADDRESS:

223. APPLICANT'S ADDRESS:

224. APPLICANT'S ADDRESS:

225. APPLICANT'S ADDRESS:

226. APPLICANT'S ADDRESS:

227. APPLICANT'S ADDRESS:

228. APPLICANT'S ADDRESS:

229. APPLICANT'S ADDRESS:

230. APPLICANT'S ADDRESS:

231. APPLICANT'S ADDRESS:

232. APPLICANT'S ADDRESS:

233. APPLICANT'S ADDRESS:

234. APPLICANT'S ADDRESS:

235. APPLICANT'S ADDRESS:

236. APPLICANT'S ADDRESS:

237. APPLICANT'S ADDRESS:

238. APPLICANT'S ADDRESS:

239. APPLICANT'S ADDRESS:

240. APPLICANT'S ADDRESS:

241. APPLICANT'S ADDRESS:

242. APPLICANT'S ADDRESS:

243. APPLICANT'S ADDRESS:

244. APPLICANT'S ADDRESS:

245. APPLICANT'S ADDRESS:

246. APPLICANT'S ADDRESS:

247. APPLICANT'S ADDRESS:

248. APPLICANT'S ADDRESS:

249. APPLICANT'S ADDRESS:

250. APPLICANT'S ADDRESS:

251. APPLICANT'S ADDRESS:

252. APPLICANT'S ADDRESS:

253. APPLICANT'S ADDRESS:

254. APPLICANT'S ADDRESS:

255. APPLICANT'S ADDRESS:

256. APPLICANT'S ADDRESS:





17 The present invention relates to a method of preparing a polymer film, and  
18 to a polymer film prepared by the method.  
19 The polymer film prepared by the method of the present invention has  
20 excellent properties when subjected to a stress, and is suitable for use as  
21 an example of a flexible substrate for a semiconductor device, a  
22 flexible display, a flexible solar cell, a flexible battery, a flexible  
23 electrode, a flexible capacitor, a flexible antenna, a flexible sensor,  
24 a flexible PNA device, and the like.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832

[illegible]

Query Match	Col. 99	Col. 100	Col. 101	Col. 102	Col. 103	Col. 104	Col. 105	Col. 106	Col. 107	Col. 108	Col. 109	Col. 110	Col. 111	Col. 112	Col. 113	Col. 114	Col. 115	Col. 116	Col. 117	Col. 118	Col. 119	Col. 120	Col. 121	Col. 122	Col. 123	Col. 124	Col. 125	Col. 126	Col. 127	Col. 128	Col. 129	Col. 130	Col. 131	Col. 132	Col. 133	Col. 134	Col. 135	Col. 136	Col. 137	Col. 138	Col. 139	Col. 140	Col. 141	Col. 142	Col. 143	Col. 144	Col. 145	Col. 146	Col. 147	Col. 148	Col. 149	Col. 150	Col. 151	Col. 152	Col. 153	Col. 154	Col. 155	Col. 156	Col. 157	Col. 158	Col. 159	Col. 160	Col. 161	Col. 162	Col. 163	Col. 164	Col. 165	Col. 166	Col. 167	Col. 168	Col. 169	Col. 170	Col. 171	Col. 172	Col. 173	Col. 174	Col. 175	Col. 176	Col. 177	Col. 178	Col. 179	Col. 180	Col. 181	Col. 182	Col. 183	Col. 184	Col. 185	Col. 186	Col. 187	Col. 188	Col. 189	Col. 190	Col. 191	Col. 192	Col. 193	Col. 194	Col. 195	Col. 196	Col. 197	Col. 198	Col. 199	Col. 200	Col. 201	Col. 202	Col. 203	Col. 204	Col. 205	Col. 206	Col. 207	Col. 208	Col. 209	Col. 210	Col. 211	Col. 212	Col. 213	Col. 214	Col. 215	Col. 216	Col. 217	Col. 218	Col. 219	Col. 220	Col. 221	Col. 222	Col. 223	Col. 224	Col. 225	Col. 226	Col. 227	Col. 228	Col. 229	Col. 230	Col. 231	Col. 232	Col. 233	Col. 234	Col. 235	Col. 236	Col. 237	Col. 238	Col. 239	Col. 240	Col. 241	Col. 242	Col. 243	Col. 244	Col. 245	Col. 246	Col. 247	Col. 248	Col. 249	Col. 250	Col. 251	Col. 252	Col. 253	Col. 254	Col. 255	Col. 256	Col. 257	Col. 258	Col. 259	Col. 260	Col. 261	Col. 262	Col. 263	Col. 264	Col. 265	Col. 266	Col. 267	Col. 268	Col. 269	Col. 270	Col. 271	Col. 272	Col. 273	Col. 274	Col. 275	Col. 276	Col. 277	Col. 278	Col. 279	Col. 280	Col. 281	Col. 282	Col. 283	Col. 284	Col. 285	Col. 286	Col. 287	Col. 288	Col. 289	Col. 290	Col. 291	Col. 292	Col. 293	Col. 294	Col. 295	Col. 296	Col. 297	Col. 298	Col. 299	Col. 300	Col. 301	Col. 302	Col. 303	Col. 304	Col. 305	Col. 306	Col. 307	Col. 308	Col. 309	Col. 310	Col. 311	Col. 312	Col. 313	Col. 314	Col. 315	Col. 316	Col. 317	Col. 318	Col. 319	Col. 320	Col. 321	Col. 322	Col. 323	Col. 324	Col. 325	Col. 326	Col. 327	Col. 328	Col. 329	Col. 330	Col. 331	Col. 332	Col. 333	Col. 334	Col. 335	Col. 336	Col. 337	Col. 338	Col. 339	Col. 340	Col. 341	Col. 342	Col. 343	Col. 344	Col. 345	Col. 346	Col. 347	Col. 348	Col. 349	Col. 350	Col. 351	Col. 352	Col. 353	Col. 354	Col. 355	Col. 356	Col. 357	Col. 358	Col. 359	Col. 360	Col. 361	Col. 362	Col. 363	Col. 364	Col. 365	Col. 366	Col. 367	Col. 368	Col. 369	Col. 370	Col. 371	Col. 372	Col. 373	Col. 374	Col. 375	Col. 376	Col. 377	Col. 378	Col. 379	Col. 380	Col. 381	Col. 382	Col. 383	Col. 384	Col. 385	Col. 386	Col. 387	Col. 388	Col. 389	Col. 390	Col. 391	Col. 392	Col. 393	Col. 394	Col. 395	Col. 396	Col. 397	Col. 398	Col. 399	Col. 400	Col. 401	Col. 402	Col. 403	Col. 404	Col. 405	Col. 406	Col. 407	Col. 408	Col. 409	Col. 410	Col. 411	Col. 412	Col. 413	Col. 414	Col. 415	Col. 416	Col. 417	Col. 418	Col. 419	Col. 420	Col. 421	Col. 422	Col. 423	Col. 424	Col. 425	Col. 426	Col. 427	Col. 428	Col. 429	Col. 430	Col. 431	Col. 432	Col. 433	Col. 434	Col. 435	Col. 436	Col. 437	Col. 438</
-------------	---------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	------------

—

[illegible]

—

—

# WALL

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: the control group (CG) and the experimental group (EG). The CG was divided into two subgroups: the control group (CG) and the control group (CG). The EG was divided into two subgroups: the experimental group (EG) and the experimental group (EG). The subjects were divided into two groups: the control group (CG) and the experimental group (EG). The CG was divided into two subgroups: the control group (CG) and the control group (CG). The EG was divided into two subgroups: the experimental group (EG) and the experimental group (EG).

[illegible][illegible][illegible]

Figure 1. The effect of the *h* parameter on the accuracy of the  $\hat{\theta}$  estimator. The figure shows the mean squared error (MSE) of the  $\hat{\theta}$  estimator for different values of  $h$  (0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1) and for different values of  $\theta$  (0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1). The MSE is plotted against  $h$  for each value of  $\theta$ . The MSE generally decreases as  $h$  increases, and the rate of decrease is faster for larger values of  $\theta$ .

	(c)
	(d)
	(e)

XX XX

$$\{(\cdot) = N(V) - [g^{\frac{1}{2}} g^{\frac{1}{2}}] \} \quad , \quad \{(\cdot) = [g^{\frac{1}{2}} g^{\frac{1}{2}}] \}$$

VII. ANALYSIS OF THE DATA

1. *Introduction*

[illegible]

**PII** Isolated or recombinant polyphosphatase (7.11 units/mg) yields, according to the method of Pridmore and Smith (1976), a single band on SDS-PAGE. This band can be stained with Coomassie Brilliant Blue G250, or it can be stained with Coomassie Brilliant Blue G250 after transfer to a nitrocellulose membrane.

[illegible]

The present invention describes a number of peptides which are derived from cell cycle checkpoints when administered to a cell. They act by inhibiting cdk1 and cdk2 kinases, and may be derived from cdk1, cdk2, their peptides, or examples of which is shown below, are used in the treatment of cancer. The inhibition of progression through one of the checkpoints of the cell cycle allows DNA damage and cell cycle arrest.

[illegible]

Century Match  
Rest Tour Summer  
Marching

[illegible]

112      **Journal of**  
 113      **Mathematical**  
 114      **Analysis and Applications**  
 115      **Volume 100**  
 116      **Number 1**  
 117      **January 1984**  
 118      **Published by**  
 119      **Marcel Dekker, Inc.**  
 120      **360 Madison Avenue**  
 121      **New York, N.Y. 10017**  
 122      **U.S.A.**  
 123      **and**  
 124      **Marcel Dekker, Inc.**  
 125      **232 Avenue of the Americas**  
 126      **New York, N.Y. 10010**  
 127      **U.S.A.**  
 128      **and**  
 129      **Marcel Dekker, Inc.**  
 130      **31 West 2nd Street**  
 131      **Amsterdam, The Netherlands**  
 132      **1017 CA**  
 133      **U.S.A.**  
 134      **and**  
 135      **Marcel Dekker, Inc.**  
 136      **31 West 2nd Street**  
 137      **Amsterdam, The Netherlands**  
 138      **1017 CA**  
 139      **U.S.A.**  
 140      **and**  
 141      **Marcel Dekker, Inc.**  
 142      **31 West 2nd Street**  
 143      **Amsterdam, The Netherlands**  
 144      **1017 CA**  
 145      **U.S.A.**  
 146      **and**  
 147      **Marcel Dekker, Inc.**  
 148      **31 West 2nd Street**  
 149      **Amsterdam, The Netherlands**  
 150      **1017 CA**  
 151      **U.S.A.**  
 152      **and**  
 153      **Marcel Dekker, Inc.**  
 154      **31 West 2nd Street**  
 155      **Amsterdam, The Netherlands**  
 156      **1017 CA**  
 157      **U.S.A.**  
 158      **and**  
 159      **Marcel Dekker, Inc.**  
 160      **31 West 2nd Street**  
 161      **Amsterdam, The Netherlands**  
 162      **1017 CA**  
 163      **U.S.A.**  
 164      **and**  
 165      **Marcel Dekker, Inc.**  
 166      **31 West 2nd Street**  
 167      **Amsterdam, The Netherlands**  
 168      **1017 CA**  
 169      **U.S.A.**  
 170      **and**  
 171      **Marcel Dekker, Inc.**  
 172      **31 West 2nd Street**  
 173      **Amsterdam, The Netherlands**  
 174      **1017 CA**  
 175      **U.S.A.**  
 176      **and**  
 177      **Marcel Dekker, Inc.**  
 178      **31 West 2nd Street**  
 179      **Amsterdam, The Netherlands**  
 180      **1017 CA**  
 181      **U.S.A.**  
 182      **and**  
 183      **Marcel Dekker, Inc.**  
 184      **31 West 2nd Street**  
 185      **Amsterdam, The Netherlands**  
 186      **1017 CA**  
 187      **U.S.A.**  
 188      **and**  
 189      **Marcel Dekker, Inc.**  
 190      **31 West 2nd Street**  
 191      **Amsterdam, The Netherlands**  
 192      **1017 CA**  
 193      **U.S.A.**  
 194      **and**  
 195      **Marcel Dekker, Inc.**  
 196      **31 West 2nd Street**  
 197      **Amsterdam, The Netherlands**  
 198      **1017 CA**  
 199      **U.S.A.**  
 200      **and**  
 201      **Marcel Dekker, Inc.**  
 202      **31 West 2nd Street**  
 203      **Amsterdam, The Netherlands**  
 204      **1017 CA**  
 205      **U.S.A.**  
 206      **and**  
 207      **Marcel Dekker, Inc.**  
 208      **31 West 2nd Street**  
 209      **Amsterdam, The Netherlands**  
 210      **1017 CA**  
 211      **U.S.A.**  
 212      **and**  
 213      **Marcel Dekker, Inc.**  
 214      **31 West 2nd Street**  
 215      **Amsterdam, The Netherlands**  
 216      **1017 CA**  
 217      **U.S.A.**  
 218      **and**  
 219      **Marcel Dekker, Inc.**  
 220      **31 West 2nd Street**  
 221      **Amsterdam, The Netherlands**  
 222      **1017 CA**  
 223      **U.S.A.**  
 224      **and**  
 225      **Marcel Dekker, Inc.**  
 226      **31 West 2nd Street**  
 227      **Amsterdam, The Netherlands**  
 228      **1017 CA**  
 229      **U.S.A.**  
 230      **and**  
 231      **Marcel Dekker, Inc.**  
 232      **31 West 2nd Street**  
 233      **Amsterdam, The Netherlands**  
 234      **1017 CA**  
 235      **U.S.A.**  
 236      **and**  
 237      **Marcel Dekker, Inc.**  
 238      **31 West 2nd Street**  
 239      **Amsterdam, The Netherlands**  
 240      **1017 CA**  
 241      **U.S.A.**  
 242      **and**  
 243      **Marcel Dekker, Inc.**  
 244      **31 West 2nd Street**  
 245      **Amsterdam, The Netherlands**  
 246      **1017 CA**  
 247      **U.S.A.**  
 248      **and**  
 249      **Marcel Dekker, Inc.**  
 250      **31 West 2nd Street**  
 251      **Amsterdam, The Netherlands**  
 252      **1017 CA**  
 253      **U.S.A.**  
 254      **and**  
 255      **Marcel Dekker, Inc.**  
 256      **31 West 2nd Street**  
 257      **Amsterdam, The Netherlands**  
 258      **1017 CA**  
 259      **U.S.A.**  
 260      **and**  
 261      **Marcel Dekker, Inc.**  
 262      **31 West 2nd Street**  
 263      **Amsterdam, The Netherlands**  
 264      **1017 CA**  
 265      **U.S.A.**  
 266      **and**  
 267      **Marcel Dekker, Inc.**  
 268      **31 West 2nd Street**  
 269      **Amsterdam, The Netherlands**  
 270      **1017 CA**  
 271      **U.S.A.**  
 272      **and**  
 273      **Marcel Dekker, Inc.**  
 274      **31 West 2nd Street**  
 275      **Amsterdam, The Netherlands**  
 276      **1017 CA**  
 277      **U.S.A.**  
 278      **and**  
 279      **Marcel Dekker, Inc.**  
 280      **31 West 2nd Street**  
 281      **Amsterdam, The Netherlands**  
 282      **1017 CA**  
 283      **U.S.A.**  
 284      **and**  
 285      **Marcel Dekker, Inc.**  
 286      **31 West 2nd Street**  
 287      **Amsterdam, The Netherlands**  
 288      **1017 CA**  
 289      **U.S.A.**  
 290      **and**  
 291      **Marcel Dekker, Inc.**  
 292      **31 West 2nd Street**  
 293      **Amsterdam, The Netherlands**  
 294      **1017 CA**  
 295      **U.S.A.**  
 296      **and**  
 297      **Marcel Dekker, Inc.**  
 298      **31 West 2nd Street**  
 299      **Amsterdam, The Netherlands**  
 300      **1017 CA**  
 301      **U.S.A.**  
 302      **and**  
 303      **Marcel Dekker, Inc.**  
 304      **31 West 2nd Street**  
 305      **Amsterdam, The Netherlands**  
 306      **1017 CA**  
 307      **U.S.A.**  
 308      **and**  
 309      **Marcel Dekker, Inc.**

1. *What is the main purpose of the study?*  
 2. *What are the research objectives?*  
 3. *What is the research methodology?*  
 4. *What are the results of the study?*  
 5. *What are the conclusions of the study?*  
 6. *What are the limitations of the study?*  
 7. *What are the implications of the study?*  
 8. *What are the future research directions?*  
 9. *What are the contributions of the study?*  
 10. *What are the key findings of the study?*

AAV30262  
 21 AAV30262 standard; Peptide: 11 AA.  
 XX  
 AA V30262  
 XX  
 21 21, 2001 (first entry)  
 XX  
 Human Chk2 kinase inhibitory peptide #1993.  
 XX  
 Human Chk2; Chk1; Chk2; G2 checkpoint; cell cycle regulation  
 KW  
 cancer; cell proliferation; apoptosis.  
 XX  
 Synthesis.  
 XX  
 W2: 24125/6.  
 XX  
 29 MAP 2001.  
 XX  
 21 SEP 2001; 2001W; 160436  
 XX  
 22 SEP 1999; 99JP 0260596.  
 XX  
 30 NOV 1999; 99JP 0340322  
 XX  
 (CANB) JAMRAS 5: 110.  
 XX  
 Suganuma M, Kawabe T.  
 XX  
 W11: 24125/6.  
 XX  
 Isolated or recombinant polypeptide of 7 11-amino acids, useful for  
 treating cell proliferative disorders, e.g., to stop the growth of, or  
 kill cancer cells, by disrupting the G2 cell cycle arrest checkpoint.  
 XX  
 Example 2: Page 97; 126pp; English.  
 XX  
 The present invention describes a number of peptides which disrupt the G2  
 cell cycle checkpoint when administered to a cell. They act by inhibiting  
 Chk1 and Chk2 kinases, and may be derived from 636256. The peptides, an  
 example of which is shown here, are useful in the treatment of cell  
 proliferation diseases, such as cancer, as the inhibition of the Chk2  
 allows DNA damage and induces apoptosis.  
 XX  
 Sequence: 11 AA:  
 29 MAP 2001.  
 XX  
 Best Local Similarity: 94.86% (Seq: 55; 16, 2001; 160436).  
 Matches: 10; Conserved: 11; Mismatches: 5; Indels: 0; Gaps: 0.  
 29  
 1 LYESPAMPEN; 11  
 1111111111  
 10 1 LYESPAMPEN; 11  
 1111111111  
 29 MAP 2001.  
 XX  
 AAV30262  
 21 AAV30262 standard; Peptide: 11 AA.  
 XX  
 AA V30262  
 XX  
 21 21, 2001 (first entry)  
 XX  
 Human Chk2 kinase inhibitory peptide #1993.  
 XX  
 Human Chk2; Chk1; Chk2; G2 checkpoint; cell cycle regulation  
 KW  
 cancer; cell proliferation; apoptosis.  
 XX  
 Synthesis.  
 XX  
 W2: 24125/6.  
 XX  
 29 MAP 2001.  
 XX  
 21 SEP 2001; 2001W; 160436  
 XX  
 22 SEP 1999; 99JP 0260596.  
 XX  
 30 NOV 1999; 99JP 0340322  
 XX  
 (CANB) JAMRAS 5: 110.  
 XX  
 Suganuma M, Kawabe T.  
 XX  
 W11: 24125/6.  
 XX  
 Isolated or recombinant polypeptide of 7 11-amino acids, useful for  
 treating cell proliferative disorders, e.g., to stop the growth of, or  
 kill cancer cells, by disrupting the G2 cell cycle arrest checkpoint.  
 XX  
 Example 2: Page 97; 126pp; English.  
 XX  
 The present invention describes a number of peptides which disrupt the G2  
 cell cycle checkpoint when administered to a cell. They act by inhibiting  
 Chk1 and Chk2 kinases, and may be derived from 636256. The peptides, an  
 example of which is shown here, are useful in the treatment of cell  
 proliferation diseases, such as cancer, as the inhibition of the Chk2  
 allows DNA damage and induces apoptosis.  
 XX  
 Sequence: 11 AA:  
 29 MAP 2001.  
 XX  
 Best Local Similarity: 94.86% (Seq: 55; 16, 2001; 160436).  
 Matches: 10; Conserved: 11; Mismatches: 5; Indels: 0; Gaps: 0.  
 29  
 1 LYESPAMPEN; 11  
 1111111111  
 10 1 LYESPAMPEN; 11  
 1111111111  
 29 MAP 2001.  
 XX  
 AAV30262  
 21 AAV30262 standard; Peptide: 11 AA.  
 XX  
 AA V30262  
 XX  
 21 21, 2001 (first entry)  
 XX  
 Human Chk2 kinase inhibitory peptide #1993.  
 XX  
 Human Chk2; Chk1; Chk2; G2 checkpoint; cell cycle regulation  
 KW  
 cancer; cell proliferation; apoptosis.  
 XX  
 Synthesis.  
 XX  
 W2: 24125/6.  
 XX  
 29 MAP 2001.  
 XX  
 21 SEP 2001; 2001W; 160436  
 XX  
 22 SEP 1999; 99JP 0260596.  
 XX  
 30 NOV 1999; 99JP 0340322  
 XX  
 (CANB) JAMRAS 5: 110.  
 XX  
 Suganuma M, Kawabe T.  
 XX  
 W11: 24125/6.  
 XX  
 Isolated or recombinant polypeptide of 7 11-amino acids, useful for  
 treating cell proliferative disorders, e.g., to stop the growth of, or  
 kill cancer cells, by disrupting the G2 cell cycle arrest checkpoint.  
 XX  
 Example 2: Page 97; 126pp; English.  
 XX  
 The present invention describes a number of peptides which disrupt the G2  
 cell cycle checkpoint when administered to a cell. They act by inhibiting  
 Chk1 and Chk2 kinases, and may be derived from 636256. The peptides, an

XX  
 21 SEP 1999; 99JP 0260596.  
 XX  
 30 NOV 1999; 99JP 0340322.  
 XX  
 (CANB) JAMRAS 5: 110.  
 XX  
 Suganuma M, Kawabe T.  
 XX  
 W11: 24125/6.  
 XX  
 Isolated or recombinant polypeptide of 7 11-amino acids, useful for  
 treating cell proliferative disorders, e.g., to stop the growth of, or  
 kill cancer cells, by disrupting the G2 cell cycle arrest checkpoint.  
 XX  
 Example 2: Page 97; 126pp; English.  
 XX  
 The present invention describes a number of peptides which disrupt the G2  
 cell cycle checkpoint when administered to a cell. They act by inhibiting  
 Chk1 and Chk2 kinases, and may be derived from 636256. The peptides, an  
 example of which is shown here, are useful in the treatment of cell  
 proliferation diseases, such as cancer, as the inhibition of the Chk2  
 allows DNA damage and induces apoptosis.  
 XX  
 Sequence: 11 AA:  
 29 MAP 2001.  
 XX  
 Best Local Similarity: 94.86% (Seq: 55; 16, 2001; 160436).  
 Matches: 10; Conserved: 11; Mismatches: 5; Indels: 0; Gaps: 0.  
 29  
 1 LYESPAMPEN; 11  
 1111111111  
 10 1 LYESPAMPEN; 11  
 1111111111  
 29 MAP 2001.  
 XX  
 AAV30262  
 21 AAV30262 standard; Peptide: 11 AA.  
 XX  
 AA V30262  
 XX  
 21 21, 2001 (first entry)  
 XX  
 Human Chk2 kinase inhibitory peptide #1993.  
 XX  
 Human Chk2; Chk1; Chk2; G2 checkpoint; cell cycle regulation  
 KW  
 cancer; cell proliferation; apoptosis.  
 XX  
 Synthesis.  
 XX  
 W2: 24125/6.  
 XX  
 29 MAP 2001.  
 XX  
 21 SEP 2001; 2001W; 160436  
 XX  
 22 SEP 1999; 99JP 0260596.  
 XX  
 30 NOV 1999; 99JP 0340322  
 XX  
 (CANB) JAMRAS 5: 110.  
 XX  
 Suganuma M, Kawabe T.  
 XX  
 W11: 24125/6.  
 XX  
 Isolated or recombinant polypeptide of 7 11-amino acids, useful for  
 treating cell proliferative disorders, e.g., to stop the growth of, or  
 kill cancer cells, by disrupting the G2 cell cycle arrest checkpoint.  
 XX  
 Example 2: Page 97; 126pp; English.  
 XX  
 The present invention describes a number of peptides which disrupt the G2  
 cell cycle checkpoint when administered to a cell. They act by inhibiting  
 Chk1 and Chk2 kinases, and may be derived from 636256. The peptides, an















EMBL: AF157963; AAF1484.1;  
 InterPro: IPR000763; Pfam01:  
 Pfam11:2434; Pfam01:  
 Glycosyltransferase; TrnSD; TrnS;  
 QV SEQUENCE 463 AA; 47.81 MW; 46.10 pI; 9.97% GC

Query Match: 100.00% (1000/1000) (1000/1000)  
 Best Local Similarity: 100.00% (1000/1000)  
 Matches: 1000 (1000/1000) (1000/1000) (1000/1000)

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

EMBL: AF157963; AAF1484.1;  
 InterPro: IPR000763; Pfam01:  
 Pfam11:2434; Pfam01:  
 Glycosyltransferase; TrnSD; TrnS;  
 QV SEQUENCE 463 AA; 47.81 MW; 46.10 pI; 9.97% GC

Query Match: 100.00% (1000/1000) (1000/1000)  
 Best Local Similarity: 100.00% (1000/1000)  
 Matches: 1000 (1000/1000) (1000/1000) (1000/1000)

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17

QV 1 LYS SHAMFEN 10  
 DE 161 LYS SHAMFEN 17





























100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200